Treatment of p. Vivax in india with patient having fever no complications
Reading File
Finding Sources
Searching PubMed
"Plasmodium vivax" AND treatment AND India
Searching the Web
NVBDCP India P vivax malaria treatment guidelines 2025 chloroquine primaquine
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Searching the Web
India NVBDCP national malaria treatment guidelines 2023 vivax chloroquine primaquine dose
I have enough information from Harrison's 22E (2025) and other textbooks to give a comprehensive answer. Let me compile it now.
Treatment of Uncomplicated P. vivax Malaria in India
India's National Vector Borne Disease Control Programme (NVBDCP) follows a two-drug strategy for uncomplicated P. vivax: a blood schizonticide (chloroquine) + an antirelapse drug (primaquine).
1. Blood Stage Treatment — Chloroquine
| Parameter | Details |
|---|---|
| Drug | Chloroquine phosphate |
| Total dose | 25 mg base/kg over 3 days |
| Day 1 | 10 mg base/kg (usually 600 mg base in adults) |
| Day 2 | 10 mg base/kg |
| Day 3 | 5 mg base/kg |
| Route | Oral |
Chloroquine remains effective for P. vivax in India for blood-stage clearance. While chloroquine-resistant P. vivax has been sporadically reported in India, it is not yet widespread enough to change the first-line recommendation (Nallapati et al., Pathog Glob Health, 2024 [PMID 37994442]).
2. Radical Cure — Primaquine (Anti-relapse)
This is mandatory to eliminate hypnozoites (dormant liver stages) which cause relapses.
| Parameter | Details |
|---|---|
| Drug | Primaquine |
| NVBDCP / India dose | 0.25 mg base/kg/day × 14 days |
| Adult dose (approx.) | 15 mg base/day × 14 days |
| Route | Oral, with food (reduces GI side effects) |
| Duration | 14 days |
Per Harrison's 22E: "Primaquine (0.25 mg of base/kg elsewhere [outside Southeast Asia/Oceania]) should be given once daily for 14 days to patients with P. vivax or P. ovale infection after laboratory tests for G6PD deficiency."
3. Critical Pre-treatment Requirement — G6PD Testing
⚠️ G6PD deficiency must be ruled out before primaquine. Primaquine causes acute haemolytic anaemia in G6PD-deficient individuals.
- G6PD normal: Give full 14-day primaquine course
- G6PD deficient: Primaquine is contraindicated; use weekly chloroquine as suppressive therapy to prevent symptomatic relapses (primaquine cannot be given safely)
- G6PD unknown / testing unavailable: Clinical judgment — weigh risk of haemolysis vs. relapse; consider giving under supervision
A 2024 meta-analysis (Rajasekhar et al., Lancet Infect Dis [PMID 37748497]) confirmed that the 0.25 mg/kg/day × 14-day dose is associated with lower haemolysis risk than higher doses, supporting its use in India where routine G6PD testing has variable availability.
4. Special Populations
| Population | Modification |
|---|---|
| Pregnant women | Primaquine contraindicated (haemolysis risk in fetus); give chloroquine alone; defer radical cure until after delivery and breastfeeding |
| Infants < 6 months | Primaquine not recommended |
| Severe G6PD deficiency | Avoid primaquine; weekly chloroquine as suppressive prophylaxis |
5. Supportive Management
- Antipyretics: Paracetamol (acetaminophen) for fever — preferred over NSAIDs
- Hydration: Adequate oral fluids
- Follow-up: Repeat blood smear at day 3 and day 28 to confirm clearance and detect treatment failure
6. When to Escalate
Although this patient has no complications, watch for warning signs requiring hospitalisation:
- Persistent high fever beyond 48–72 h of treatment
- Haemoglobin drop / jaundice (rule out haemolysis from primaquine)
- Vomiting preventing oral therapy
- Thrombocytopenia with bleeding
- Signs of severe malaria (impaired consciousness, respiratory distress, severe anaemia Hb <7 g/dL)
Summary Regimen Card
Day 1: Chloroquine 600 mg base PO + Primaquine 15 mg base PO
Day 2: Chloroquine 600 mg base PO + Primaquine 15 mg base PO
Day 3: Chloroquine 300 mg base PO + Primaquine 15 mg base PO
Days 4–14: Primaquine 15 mg base PO once daily
(After confirming G6PD normal status)
Sources:
- Harrison's Principles of Internal Medicine, 22E (2025), Ch. 231 — Uncomplicated Malaria
- Goldman-Cecil Medicine — Protozoal Diseases
- Verma R et al. Primaquine safety in South Asia. BMJ Glob Health 2023 [PMID 38123228]
- Rajasekhar M et al. Primaquine dose and haemolysis risk. Lancet Infect Dis 2024 [PMID 37748497]
- Nallapati VT et al. CQ-resistant P. vivax in India. Pathog Glob Health 2024 [PMID 37994442]
This is a shared conversation. Sign in to Orris to start your own chat.